Gastrointestinal stromal tumours
Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
H Joensuu, A Vehtari, J Riihimäki, T Nishida… - The lancet …, 2012 - thelancet.com
Background The risk of recurrence of gastrointestinal stromal tumour (GIST) after surgery
needs to be estimated when considering adjuvant systemic therapy. We assessed …
needs to be estimated when considering adjuvant systemic therapy. We assessed …
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial
Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-
free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared …
free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared …
Risk stratification of patients diagnosed with gastrointestinal stromal tumor
H Joensuu - Human pathology, 2008 - Elsevier
Accurate risk stratification of gastrointestinal stromal tumors (GISTs) has become
increasingly important owing to emerging adjuvant systemic treatments. All GISTs have …
increasingly important owing to emerging adjuvant systemic treatments. All GISTs have …
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal …
Background Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …
KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence
H Joensuu, P Rutkowski, T Nishida… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI
stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is …
stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is …
Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour
P Hohenberger, U Ronellenfitsch… - Journal of British …, 2010 - academic.oup.com
Background This study assessed the outcomes of patients with a gastrointestinal stromal
tumour (GIST) that ruptured before or during resection. Methods The records of 23 patients …
tumour (GIST) that ruptured before or during resection. Methods The records of 23 patients …
[HTML][HTML] Gastrointestinal stromal tumor
X Zhao, C Yue - Journal of gastrointestinal oncology, 2012 - ncbi.nlm.nih.gov
Gastrointestinal stromal tumor has received a lot of attention over the last 10 years due to its
unique biologic behavior, clinicopathological features, molecular mechanisms, and …
unique biologic behavior, clinicopathological features, molecular mechanisms, and …
Diagnosis and management of gastrointestinal stromal tumors: An up-to-date literature review
Gastrointestinal stromal tumors (GISTs) are rare life-threatening forms of cancer that may
arise anywhere in the GI tract. Herein, we aimed to review the literature to describe the …
arise anywhere in the GI tract. Herein, we aimed to review the literature to describe the …
[HTML][HTML] Gastrointestinal stromal tumors: a multidisciplinary challenge
JM Sanchez-Hidalgo, M Duran-Martinez… - World journal of …, 2018 - ncbi.nlm.nih.gov
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors located
in the alimentary tract. Its usual manifestation is gastrointestinal bleeding. However, small …
in the alimentary tract. Its usual manifestation is gastrointestinal bleeding. However, small …